Arjuna Capital Sells 6,116 Shares of Novo Nordisk A/S (NYSE:NVO)

Arjuna Capital trimmed its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 11.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 47,267 shares of the company's stock after selling 6,116 shares during the quarter. Novo Nordisk A/S accounts for 1.5% of Arjuna Capital's portfolio, making the stock its 17th largest holding. Arjuna Capital's holdings in Novo Nordisk A/S were worth $5,628,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in NVO. William Blair Investment Management LLC boosted its holdings in shares of Novo Nordisk A/S by 2.3% in the 1st quarter. William Blair Investment Management LLC now owns 53,423 shares of the company's stock worth $6,860,000 after acquiring an additional 1,185 shares in the last quarter. Edmond DE Rothschild Holding S.A. acquired a new position in shares of Novo Nordisk A/S in the 1st quarter worth approximately $80,000. TD Asset Management Inc boosted its holdings in shares of Novo Nordisk A/S by 10.9% in the 1st quarter. TD Asset Management Inc now owns 1,074,022 shares of the company's stock worth $137,904,000 after acquiring an additional 105,523 shares in the last quarter. D Orazio & Associates Inc. boosted its holdings in shares of Novo Nordisk A/S by 4.4% in the 1st quarter. D Orazio & Associates Inc. now owns 8,655 shares of the company's stock worth $1,111,000 after acquiring an additional 362 shares in the last quarter. Finally, Planning Directions Inc. raised its position in Novo Nordisk A/S by 4.0% in the 1st quarter. Planning Directions Inc. now owns 2,916 shares of the company's stock worth $374,000 after purchasing an additional 112 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 0.1 %

Shares of Novo Nordisk A/S stock traded down $0.14 on Wednesday, hitting $106.93. 3,156,511 shares of the company's stock traded hands, compared to its average volume of 4,440,904. The firm's 50-day moving average price is $120.23 and its two-hundred day moving average price is $130.08. The stock has a market capitalization of $479.83 billion, a PE ratio of 34.60, a price-to-earnings-growth ratio of 1.29 and a beta of 0.42. Novo Nordisk A/S has a one year low of $94.73 and a one year high of $148.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

Analysts Set New Price Targets

NVO has been the subject of several research analyst reports. Cantor Fitzgerald restated an "overweight" rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. StockNews.com upgraded shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research report on Friday, November 1st. Finally, BMO Capital Markets dropped their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an "outperform" rating for the company in a research report on Thursday, October 17th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.